Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non-cash Items (2020 - 2023)

Barinthus Biotherapeutics (BRNS) has disclosed Non-cash Items for 4 consecutive years, with $4.1 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Non-cash Items fell 52.87% year-over-year to $4.1 million, compared with a TTM value of $4.1 million through Sep 2023, down 52.87%, and an annual FY2022 reading of $2.6 million, up 229.16% over the prior year.
  • Non-cash Items was $4.1 million for Q3 2023 at Barinthus Biotherapeutics, down from $6.5 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $19.8 million in Q2 2021 and bottomed at $2.6 million in Q4 2022.
  • Average Non-cash Items over 4 years is $10.3 million, with a median of $9.0 million recorded in 2023.
  • The sharpest move saw Non-cash Items skyrocketed 448.79% in 2021, then crashed 84.55% in 2022.
  • Year by year, Non-cash Items stood at $3.1 million in 2020, then surged by 448.79% to $17.0 million in 2021, then plummeted by 84.55% to $2.6 million in 2022, then skyrocketed by 56.55% to $4.1 million in 2023.
  • Business Quant data shows Non-cash Items for BRNS at $4.1 million in Q3 2023, $6.5 million in Q2 2023, and $9.0 million in Q1 2023.